Allergen immunotherapy effective in treating local allergic rhinitis

This article originally appeared here.
Significant improvements were found in allergen immunotherapy for local allergic rhinitis.
Significant improvements were found in allergen immunotherapy for local allergic rhinitis.

HealthDay News — Dermatophagoides pteronyssinus (DP) subcutaneous allergen immunotherapy (AIT) seems safe and effective for local allergic rhinitis (LAR), according to a study published online March 23 in Allergy.

Carmen Rondón, MD, PhD, from the IBIMA-Regional University Hospital of Málaga in Spain, and colleagues conducted a first randomized, double-blind, placebo-controlled phase II trial of DP-AIT in 36 LAR patients. Participants were randomized to Pangramin Plus DP or placebo for 24 months. Symptoms, medication scores, and medication-free days were assessed as primary end points. Secondary end points included skin test, serum specific immunoglobulin E (sIgE) and IgG4, nasal allergen provocation test (NAPT), and adverse events.

The researchers observed significant improvements in primary and secondary end points for AIT-DP versus placebo. A significant and marked increase was seen in allergen tolerance after 12 months of AIT-DP, with negative NAPT in 50% of patients; significant increases were seen in serum sIgG4. Immunotherapy was well tolerated, with no reports of systemic reactions.

"This study demonstrated that AIT-DP is a safe and clinically effective treatment for LAR, confirming that LAR is a new indication for AIT," the authors write.


  1. Rondon C, Campo P, Salas M, et al. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: Double-blind placebo-controlled clinical trial. Allergy. 2016; doi: 10.1111/all.12889
You must be a registered member of Clinical Advisor to post a comment.

Next Article in Allergy and Immunology Information Center

Sign Up for Free e-newsletters